Does Zepbound Make You Tired? Fatigue, Headaches and the Nights You Can't Sleep

The short answer

Yes, for a minority. In Zepbound's weight-loss trials, fatigue was reported by 5% to 7% of people depending on dose, against 3% on placebo¹. Wegovy's figure is 11% against 5%². Headache shows up in Wegovy's label but not in Zepbound's, and insomnia is not listed in either one.

Elena Voss is a mother writing for mothers, not a treating clinician, and holds no medical license. Every clinical figure here is cited inline to its primary source, the trial or the FDA label, so you can check it. This is background reading, not medical advice.

That gap between what the labels count and what people describe is the useful part of this page. If you are a mother running on broken sleep, the drug is one suspect among several, and the label cannot tell you which cause explains your symptoms.

What the labels actually count

Each label lists the reactions that showed up in at least 2% of people on the drug and more often than on placebo. Here is how tiredness, headache and dizziness came out.

Sources: Zepbound Table 1¹; Wegovy Tables 3 and 4².

Three things stand out. Zepbound's fatigue line climbs gently with dose, from 5% at the lowest maintenance dose to 7% at the highest, and its definition is broad: it pools fatigue, weakness, lethargy and a general sense of feeling unwell¹. Wegovy's headache excess is small, 14% against 10% on placebo, which means most of the headaches in that arm would have happened anyway². And Ozempic, studied in people with type 2 diabetes, names fatigue only in a list of reactions above 0.4%, with headache appearing only in post-approval reports where frequency cannot be estimated³.

Do not read across the rows to rank the drugs. The Wegovy label itself warns that adverse-reaction rates from one drug's trials cannot be directly compared with another's, because the trials ran under different conditions².

Why a weekly shot can leave you flat

The labels point to a few mechanisms you can act on. The first is blood pressure. Low blood pressure was reported in 1.6% of people on Zepbound against 0.1% on placebo, more often in those already taking blood pressure medicine (2.2% against 1.2%), and it occurred alongside stomach side effects and dehydration¹. On Wegovy, low blood pressure ran 1.3% against 0.4%, and fainting 0.8% against 0.2%². If you feel washed out and lightheaded when you stand, that pattern is worth reporting, especially if you take a blood pressure pill.

The second is fluid. Both labels warn that nausea, vomiting and diarrhea can dehydrate you badly enough to affect the kidneys, and tell you to drink fluids and report stomach symptoms that will not settle^1,2. Fatigue and headache are common companions of a dehydrated week.

The third is blood sugar, but only for some readers. In the Zepbound trial of people with type 2 diabetes, low blood sugar was reported in 4.2% against 1.3% on placebo, and the medication guide lists drowsiness and headache among its signs; the risk rises with insulin or a sulfonylurea¹.

The fourth is simply eating much less. A day of coffee and a few bites of your children's leftovers is a low-energy day on any drug.

The checklist before you blame the shot

Fatigue in a mother has crowded causes, and several are easy to miss because they came first. Before you change your dose, go through these with your clinician:

• Sleep debt. A newborn, a toddler who wakes at 4 a.m. or a teenager's late pickup can account for all of it. Track a week before deciding the drug did this.
• Iron and B12. Heavy periods and recent pregnancy both drain iron, and smaller meals can cut intake further. Our guide to protein, iron and B12 on a GLP-1 covers what is and is not known.
• Thyroid. Thyroid trouble is common in women and causes exactly this kind of tiredness. See GLP-1s and your thyroid.
• Sleep apnea. Snoring, morning headaches and daytime sleepiness point here, and Zepbound is itself approved to treat it. Read sleep apnea in women.
• Mood. Flatness and low drive can be low mood rather than low energy. See mood changes on a GLP-1.

Ask whether bloodwork makes sense. A tired body that turns out to be iron-deficient needs iron, not a lower dose.

Headaches: what the data can and cannot say

Online, headache is one of the loudest complaints. A study of 59,293 Facebook posts about GLP-1 drugs from 2022 to 2024 found that headache was the adverse event most often mentioned in posts about tirzepatide, at 1.86% of those posts⁴. Headache does not appear in the Zepbound label's common adverse-reaction table¹.

Both can be true. Social posts count what people notice and attribute to the drug, and they cannot separate a drug headache from a dehydration headache, a caffeine-withdrawal headache or a sleepless-night headache. A missing row in the trial label cannot identify the cause of your headache either. Headache is nonspecific; new, persistent or concerning symptoms need assessment rather than an assumed explanation.

What about insomnia?

Neither the Zepbound nor the Wegovy label lists insomnia^1,2. In the Facebook study, insomnia mentions clustered tightly with anxiety and depression mentions rather than with stomach symptoms⁴, which fits sleeplessness tracking mood more than dose. Zepbound points the other way in one group: in its sleep apnea trials, people on the drug reported less sleep-related impairment than those on placebo¹.

If you are lying awake, the more productive questions are about worry, heartburn after a late meal and a racing heart. Our page on heart rate and palpitations covers the last of those.

When tiredness is a reason to call

Call your prescriber the same day if fatigue comes with vomiting or diarrhea that will not stop, very little urine, or dizziness when you stand. The Zepbound medication guide says to stop the drug and call right away for severe stomach pain that will not go away, sometimes felt through to the back, and to stop and get medical help right away for swelling of the face or throat, trouble breathing, fainting or a very rapid heartbeat¹. If you use insulin or a sulfonylurea, treat shakiness, sweating and confusion as possible low blood sugar first.

For the wider picture of side effects and how to get through dose increases, see managing GLP-1 side effects and the GLP-1 providers for women board.

Where this sits on the evidence scale

The fatigue numbers are solid: placebo-controlled trials in thousands of adults, most of them women, summarized in two current labels. The headache picture is mixed, with a small excess in the Wegovy table, no headache row in the Zepbound common adverse-reaction table, and a much louder online signal that cannot prove cause. The labels discussed here do not establish insomnia as an adverse reaction, which does not identify the cause of an individual patient’s sleep problems. Nobody has studied fatigue on these drugs in postpartum mothers, so the checklist above is the best guide we have until that research exists.